AI Engines For more Details: Perplexity Kagi Labs You
Suppression of Ovulation: Gestrinone suppresses ovulation, which can prevent the release of eggs from the ovaries. This effect can be beneficial in the treatment of endometriosis, as it helps to reduce menstrual pain and the growth of endometrial tissue.
Reduction of Endometrial Tissue: Gestrinone can help to reduce the growth and proliferation of endometrial tissue outside the uterus. By inhibiting the growth of endometrial implants, gestrinone can alleviate symptoms such as pelvic pain, dysmenorrhea (painful menstruation), and dyspareunia (painful intercourse) associated with endometriosis.
Androgenic Effects: Gestrinone has weak androgenic (male hormone-like) properties, which may lead to side effects such as acne, oily skin, and increased facial or body hair growth (hirsutism) in some individuals. These androgenic effects are usually mild but can be bothersome for some patients.
Menstrual Irregularities: Gestrinone can cause menstrual irregularities, including irregular bleeding or spotting between periods (breakthrough bleeding). Some women may experience changes in the duration or frequency of their menstrual cycles while taking gestrinone.
Weight Gain: Weight gain is a common side effect of gestrinone therapy. This weight gain may be due to fluid retention or changes in metabolism associated with the medication.
Breast Changes: Some women may experience breast tenderness, swelling, or enlargement while taking gestrinone. These breast changes are usually mild and reversible upon discontinuation of the medication.
Mood Changes: Gestrinone may affect mood and emotional well-being in some individuals. Mood swings, irritability, or changes in libido (sex drive) have been reported as potential side effects of gestrinone therapy.
Liver Function: Gestrinone can affect liver function, and regular monitoring of liver enzymes may be necessary during treatment. Rarely, gestrinone may cause liver toxicity or liver damage, which may manifest as jaundice (yellowing of the skin or eyes), abdominal pain, or dark urine.
Cardiovascular Effects: Long-term use of gestrinone may have cardiovascular effects, including changes in lipid levels (cholesterol and triglycerides) and blood pressure. These effects should be monitored regularly, especially in women with pre-existing cardiovascular risk factors.
Bone Density: Prolonged use of gestrinone may lead to decreased bone density (osteoporosis) in some individuals. Regular monitoring of bone density and supplementation with calcium and vitamin D may be recommended to mitigate this risk.
Fertility: Gestrinone is not a contraceptive, and women of childbearing age should use effective contraception while taking gestrinone, as it can cause fetal harm if used during pregnancy.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.1 | -0.1 | |
ADHD | 1.2 | 0.2 | 5 |
Age-Related Macular Degeneration and Glaucoma | 0 | 0.1 | 0 |
Allergic Rhinitis (Hay Fever) | 0.4 | 0.2 | 1 |
Allergies | 0.6 | 0.2 | 2 |
Allergy to milk products | 0.4 | 0.3 | 0.33 |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 1 | 0.9 | 0.11 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.2 | 2.5 |
Ankylosing spondylitis | 0.7 | 0.3 | 1.33 |
Anorexia Nervosa | 0.1 | 0.2 | -1 |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.1 | 0.2 | -1 |
Atherosclerosis | 0.2 | 0 | 0 |
Atrial fibrillation | 0.6 | 0.6 | 0 |
Autism | 1.3 | 1.6 | -0.23 |
Barrett esophagus cancer | 0.1 | 0.1 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.4 | 0.3 | 0.33 |
Brain Trauma | 0.1 | 0.2 | -1 |
Carcinoma | 0.4 | 0.3 | 0.33 |
Celiac Disease | 0.7 | 0.5 | 0.4 |
Cerebral Palsy | 0.1 | 0.2 | -1 |
Chronic Fatigue Syndrome | 1.2 | 1.6 | -0.33 |
Chronic Kidney Disease | 0.4 | 0.3 | 0.33 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.3 | -2 |
Chronic Urticaria (Hives) | 0.3 | 0.5 | -0.67 |
Coagulation / Micro clot triggering bacteria | 0.4 | 0 | 0 |
Colorectal Cancer | 1.3 | 0.1 | 12 |
Constipation | 0.6 | 0 | 0 |
Coronary artery disease | 0.2 | -0.2 | |
COVID-19 | 1.8 | 1.7 | 0.06 |
Crohn's Disease | 2.1 | 1 | 1.1 |
cystic fibrosis | 0.3 | 0.3 | 0 |
deep vein thrombosis | 0.3 | 0 | 0 |
Depression | 2.3 | 1.6 | 0.44 |
Dermatomyositis | 0.1 | -0.1 | |
Eczema | 0.1 | 0.4 | -3 |
Endometriosis | 0.9 | 0.9 | |
Eosinophilic Esophagitis | 0.1 | 0.1 | |
Epilepsy | 0.8 | 0.5 | 0.6 |
Fibromyalgia | 0.3 | 1.4 | -3.67 |
Functional constipation / chronic idiopathic constipation | 1.5 | 1 | 0.5 |
gallstone disease (gsd) | 0.2 | 0.2 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.7 | |
Generalized anxiety disorder | 0.4 | 0.6 | -0.5 |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.3 | 0 | 0 |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 0.3 | 0.2 | 0.5 |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.7 | 0.7 | |
hyperglycemia | 0.1 | 0.3 | -2 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 0.4 | 1 | -1.5 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 1 | -1 | |
Inflammatory Bowel Disease | 0.9 | 1.3 | -0.44 |
Insomnia | 0.2 | 0.2 | 0 |
Intelligence | 0.8 | 0.2 | 3 |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 0.6 | 1.4 | -1.33 |
Liver Cirrhosis | 0.8 | 0.5 | 0.6 |
Long COVID | 1.3 | 0.8 | 0.63 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.1 | 0.1 | |
ME/CFS with IBS | 0.7 | -0.7 | |
ME/CFS without IBS | 0.1 | 0.4 | -3 |
Menopause | 0.3 | 0.3 | |
Metabolic Syndrome | 1.3 | 2.2 | -0.69 |
Mood Disorders | 2.5 | 1.6 | 0.56 |
Multiple Sclerosis | 0.4 | 1 | -1.5 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | 0 |
Neuropathy (all types) | 0.1 | -0.1 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.6 | -1 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 0.8 | 0.8 | 0 |
obsessive-compulsive disorder | 1.9 | 0.6 | 2.17 |
Osteoarthritis | 0.3 | 0.3 | |
Osteoporosis | 0.3 | 0.2 | 0.5 |
Parkinson's Disease | 0.6 | 0.8 | -0.33 |
Polycystic ovary syndrome | 0.7 | 0.1 | 6 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0.1 | 0.1 | 0 |
primary biliary cholangitis | 0.6 | -0.6 | |
Psoriasis | 0.6 | 0.9 | -0.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 0.9 | 0.22 |
Rosacea | 0.1 | 0 | 0 |
Schizophrenia | 1.2 | 0.3 | 3 |
scoliosis | 0.2 | 0.2 | |
Sjögren syndrome | 0.4 | 0.9 | -1.25 |
Sleep Apnea | 0.4 | 0.5 | -0.25 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.1 | 2 |
Stress / posttraumatic stress disorder | 0.7 | 0.5 | 0.4 |
Systemic Lupus Erythematosus | 1 | 0.1 | 9 |
Tic Disorder | 0.3 | 0.2 | 0.5 |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 1.3 | 0.4 | 2.25 |
Type 2 Diabetes | 1.7 | 2.1 | -0.24 |
Ulcerative colitis | 0.6 | 1.8 | -2 |
Unhealthy Ageing | 1.4 | 0.3 | 3.67 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.